rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    PMN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      ProMIS Neurosciences, Inc. Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinancePMN
      ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
      Nov 12Yahoo FinancePMN
      ProMIS Neurosciences at stifel 2026 healthcare conference: safety focus
      Nov 11Investing.comPMNSF
      ProMIS Neurosciences to Participate in Upcoming Conferences in November
      Nov 5Yahoo FinancePMN
      ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
      Nov 3Yahoo FinancePMN
      Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade
      Oct 29Yahoo FinancePMN
      H.C. Wainwright reiterates ProMIS Neurosciences stock rating on ARIA concerns
      Oct 16Investing.comPMN
      H.C. Wainwright reiterates ProMIS Neurosciences stock rating on new hire
      Oct 12Investing.comPMN
      ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer
      Oct 6Investing.comPMN
      ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

      Former senior Biogen and Roche executive brings deep experience across Alzheimer’s clinical development, launch readiness, commercialization and global medical strategy Appointment strengthens commercial and development leadership as PMN310 advances toward 12-month topline data expected in Q1 2027 CAMBRIDGE, Mass.,, Oct. 06, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a clinical-stage biotechnology company developing therapeutics targeting toxic

      Oct 6Yahoo FinancePMN
      ProMIS Neurosciences at H.C. Wainwright conference: safety stands out
      Sep 15Investing.comPMN
      ProMIS Neurosciences at Moody Capital conference: safety sets it apart
      Sep 10Investing.comPMN
      ProMIS Neurosciences at Cantor conference: Alzheimer’s drug gains focus
      Sep 9Investing.comPMN
      ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

      CAMBRIDGE, Mass, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, today announced that it will participate in upcoming September 2026 conferences and key investor events, and will be available for one-on-one meetings. Conference details below: September 9-11: Cantor Global Healthcare ConferenceLocation: New York, NYFires

      Sep 1Yahoo FinancePMN

      This is the newest page. Registered accounts read further back.